Opioid Pharmacology

Molecular Mechanisms

• Mu (μ) receptor activation (the primary site of analgesic and reinforcing effects) opens G-protein-coupled inward rectifier K+ channels, causing membrane hyperpolarization and reduced neuronal excitability. This decreases both the frequency and amplitude of action potentials in pain-processing neurons within the dorsal horn and higher brain centers.
• Inhibition of adenylyl cyclase reduces cAMP levels, resulting in decreased neurotransmitter release (substance P, glutamate) from presynaptic terminals in nociceptive pathways.
• GABA and glycine disinhibition occurs through opioid effects on inhibitory interneurons in the spinal cord, paradoxically reducing inhibition and contributing to analgesic effects through complex circuit modulation.

Cellular and Circuit-Level Mechanisms

• Dorsal horn modulation: Opioids activate inhibitory pathways in laminae I-II (substantia gelatinosa), reducing nociceptive transmission from C and Aδ fibers. This gate-control mechanism directly suppresses pain signal propagation to higher centers.
• Brainstem and midbrain circuits: Opioids enhance descending inhibitory pathways originating from the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), which project to the spinal dorsal horn and suppress nociceptive neurotransmission. This is mediated by noradrenergic and serotonergic systems.
• Limbic system effects: Activation of μ receptors in the nucleus accumbens, ventral tegmental area (VTA), and anterior insula produces dopamine release, underlying the rewarding properties and addiction potential. Chronic opioid use causes desensitization of these reward circuits, requiring escalating doses (tolerance).

Organ-Level Physiological Effects

• Central nervous system: Depression of respiratory centers in the medulla (dose-dependent, leading to respiratory depression and overdose risk); suppression of cough reflex; pupillary constriction (miosis) via μ3 receptor effects; sedation and drowsiness from cortical depression.
• Gastrointestinal system: Increased tone in circular muscle, decreased propulsive contractions, and enhanced sphincter tone lead to constipation (very common), which is mediated by peripheral μ receptors and is not subject to tolerance.
• Cardiovascular: Histamine release (morphine, codeine) causing vasodilation and hypotension; bradycardia from vagal stimulation; potential for syncope in opioid-naïve patients.
• Endocrine disruption: Chronic opioid use suppresses GnRH secretion, reducing testosterone and estrogen levels, causing hypogonadism, decreased libido, and sexual dysfunction.

Neuroadaptation and Dependence

• Tolerance develops through μ-opioid receptor desensitization (G-protein coupling uncoupling), β-arrestin recruitment, and receptor internalization, requiring higher doses for equivalent effects.
• Physical dependence involves upregulation of adenylyl cyclase and other compensatory intracellular mechanisms; when opioids are withdrawn, unopposed activity of these systems produces withdrawal symptoms (hyperalgesia, dysphoria, autonomic hyperactivity).
• Psychological dependence stems from altered dopaminergic reward processing and conditioned responses, forming the basis of opioid use disorder.

Clinical Indications for Opioid Use

• Acute severe pain: Post-surgical pain, trauma, acute myocardial infarction, acute pancreatitis, renal colic
• Chronic cancer pain: Malignancy-related neuropathic, visceral, and somatic pain; opioid tolerance is managed through dose escalation
• Chronic non-cancer pain: Low back pain, neuropathic pain, fibromyalgia (though efficacy for non-cancer chronic pain is debated); increased risk for opioid use disorder in this population
• Palliative/hospice care: End-of-life pain management and dyspnea relief

Risk Factors for Opioid Use Disorder and Adverse Outcomes

• Demographic factors: Age 18–25, male gender (though rates are equalizing), white race (in U.S. epidemiological context)
• Psychiatric comorbidity: Depression, anxiety, bipolar disorder, PTSD, attention-deficit/hyperactivity disorder
• Personal/family history: Prior substance use disorder, family history of addiction, adverse childhood experiences
• Dosing practices: Higher initial doses (≥50 mg morphine equivalent daily), rapid dose escalation, concurrent benzodiazepine use
• Medication factors: Extended-release formulations, potent synthetic opioids (fentanyl, carfentanil), heroin, and illicit fentanyl analogs
• Socioeconomic factors: Low socioeconomic status, unemployment, social isolation, limited access to addiction treatment
• Iatrogenic factors: Inadequate pain education, failure to screen for addiction risk, lack of urine drug screening, poor monitoring

Acute Opioid Effects (Therapeutic)

• Analgesia: Dose-dependent reduction in pain perception without loss of consciousness
• Euphoria/dysphoria: Sense of well-being and pleasure (μ receptor), or dysphoria (κ receptor)
• Sedation and drowsiness: CNS depression affecting alertness and cognitive function
• Miosis (pinpoint pupils): Characteristic sign of opioid effect, mediated by μ3 receptors in the Edinger-Westphal nucleus; notably preserved during opioid-induced respiratory depression (unlike barbiturate or benzodiazepine overdose where pupils dilate)

Acute Opioid Overdose/Toxidrome

• Classic triad: Respiratory depression (most life-threatening), CNS depression (altered consciousness/coma), and miosis
• Severe respiratory depression: Bradypnea (respiratory rate <8–10/min), hypoxemia, hypercapnia, potential for cardiac arrest
• Altered mental status: Drowsiness progressing to unresponsiveness, coma, and death
• Pulmonary edema: Non-cardiogenic (possibly due to direct lung injury or increased venous return), producing pink frothy sputum
• Bradycardia and hypotension: From CNS depression and peripheral vasodilation
• Seizures: Rare; more common with tramadol, propoxyphene, or very high doses
• Muscle rigidity: Particularly with potent synthetic opioids (fentanyl, remifentanil); includes truncal rigidity and "wooden chest syndrome" (fentanyl paradox)

Chronic Opioid Use Effects

• Constipation: Most bothersome; opioid-induced bowel dysfunction (OIBD) with reduced stool frequency and increased straining
• Hypogonadism: Erectile dysfunction, loss of libido, amenorrhea, infertility (in both sexes)
• Cognitive impairment: "Opioid fog," reduced attention and memory, impaired driving ability
• Sleep disturbance: Paradoxically worsened by opioids despite sedation (sleep apnea exacerbation, reduced REM)
• Immune suppression: Reduced NK cell activity; increased infection risk
• Hyperalgesia: Paradoxical increased pain sensitivity with chronic use, particularly neuropathic pain
• Dependent behavior patterns: Drug-seeking, "clock watching," requesting early refills, accessing multiple providers ("doctor shopping")

Opioid Withdrawal Syndrome

• Timeline: Symptom onset depends on opioid half-life: short-acting (6–12 hours), long-acting like methadone (24–48 hours)
• Autonomic symptoms: Lacrimation, rhinorrhea, diaphoresis, tachycardia, hypertension, mydriasis (dilated pupils—opposite of intoxication)
• Somatic symptoms: Myalgias, arthralgias, piloerection ("gooseflesh"), insomnia, restlessness
• GI symptoms: Nausea, vomiting, diarrhea, abdominal cramping, anorexia
• Psychological symptoms: Dysphoria, anxiety, irritability, craving
• Note: Withdrawal is intensely uncomfortable but not directly life-threatening (unlike alcohol or benzodiazepine withdrawal)

Opioid Use Disorder (Diagnostic Features)

• Criteria (DSM-5): ≥2 of 11 criteria over 12 months, including: taking opioids in larger amounts/longer than intended; persistent desire or unsuccessful efforts to cut down; great deal of time obtaining/using opioids; craving; recurrent use resulting in failure to fulfill obligations; continued use despite interpersonal/social problems; tolerance; withdrawal; use despite hazard or harm; neglect of other activities
• Severity: Mild (2–3 criteria), moderate (4–5 criteria), severe (≥6 criteria)

Clinical Assessment

• Detailed history: Duration and pattern of opioid use, route (oral, intranasal, IV, transdermal), concurrent substance use, past addiction treatment, social/psychiatric history
• Physical examination: Assess for signs of intoxication (miosis, drowsiness, slurred speech), withdrawal (mydriasis, diaphoresis, piloerection), or complications (injection sites for abscess/endocarditis, signs of hepatitis)
• Validated screening tools: OARRS (Opioid Addiction Risk Rating Scale), SOAPP (Screener and Opioid Assessment for Patients with Pain), ORT (Opioid Risk Tool)—useful for predicting addiction risk before initiating opioids

Urine Drug Screening (UDS)

• Immunoassay: Initial screening for opiates (morphine, codeine), but does not detect synthetic opioids like fentanyl, tramadol, buprenorphine, methadone
• Liquid chromatography-mass spectrometry (LC-MS): Gold standard confirmatory test; detects specific opioids and metabolites; essential for monitoring patients on buprenorphine or methadone, or suspected illicit opioid use
• Interpretation: Positive opiates on immunoassay but negative on LC-MS suggests poppy seed ingestion (false positive) or heroin use (which metabolizes to morphine and codeine)
• Expected findings: Patients on prescribed opioids should have detectable opioid levels; unexpected negative results suggest non-adherence or diversion

Laboratory Evaluation

• Liver function tests: Baseline and periodic assessment, especially if hepatitis C co-infection suspected
• HIV testing: Recommended for all with opioid use disorder, particularly IV users
• Hepatitis B and C serology: Risk of bloodborne infection transmission
• Complete blood count: Assess for anemia, immune compromise
• Renal function: Important for methadone metabolism; some opioids renally cleared
• Albumin/prealbumin: Nutritional status in chronic users
• Lipid panel and glucose: Risk factors for chronic disease

Diagnostic Criteria Specific to Opioid Disorders

• Opioid Use Disorder (DSM-5): As outlined above; diagnosed by clinical interview
• Opioid Intoxication: Use within last 12 hours, behavioral/cognitive changes, ≥2 of: constricted pupils, drowsiness, impaired cognition, with clear evidence of use
• Opioid Withdrawal: After cessation/dose reduction in opioid-dependent individual, ≥3 of: dysphoria, insomnia, anxiety, GI distress, muscle aches, lacrimation, mydriasis, piloerection, sweating, yawning, restlessness, within 6–24 hours (short-acting) to 24–48 hours (long-acting)
• Opioid-Induced Sleep Apnea: Objective evidence of sleep apnea emerging or worsening with opioid use; considered an opioid-related disorder

Imaging and Specialized Studies

• Chest X-ray: If respiratory depression suspected, assess for pulmonary edema, aspiration
• ECG: If cardiac complications or arrhythmias concern; prolonged QT interval with methadone
• Sleep study (polysomnography): If opioid-induced sleep apnea suspected
• Cross-sectional imaging: CT/MRI if structural complications (epidural abscess, subdural hematoma from trauma) are considerations

Acute Opioid Overdose Management

First-Line: Opioid Antagonist

• Naloxone (Narcan): Competitive antagonist at all opioid receptors, particularly μ receptors; fastest onset of action (2–3 minutes IV, 3–5 minutes IM/intranasal)
• Dosing: IV 0.4–2 mg bolus, repeated every 2–3 minutes up to 10 mg; intranasal 2 mg per nostril
• Mechanism: Displaces opioids from receptors, rapidly reversing opioid effects within minutes
• Drawbacks: Short half-life (30–90 minutes) vs. long-acting opioids (methadone, extended-release morphine); risk of acute withdrawal if excessive dosing; may require repeated dosing or continuous infusion for long-acting opioids
• Dosing algorithm: Give 0.4 mg IV, assess for improvement in respiratory rate/consciousness; if inadequate response at 2–3 minutes, double dose and repeat; continue escalation
• Continuous infusion: For long-acting opioid overdose, calculate 2/3 of IV bolus dose that reversed overdose and infuse per hour
• Naloxone availability: FDA-approved nasal spray kits widely available; community distribution programs encouraged; laypersons can administer

Second-Line: Supportive Care

• Airway management: Bag-valve-mask ventilation if spontaneous breathing inadequate; endotracheal intubation if unable to protect airway or achieve adequate oxygenation
• Supplemental oxygen: Target SpO2 >90%; use to manage hypoxemia from respiratory depression
• IV access and fluids: Establish IV line; normal saline for hypotension correction; monitor for pulmonary edema development
• Cardiac monitoring: Continuous telemetry; obtain ECG to assess for dysrhythmias
• Temperature management: Passive rewarming if hypothermia present (common in prolonged overdose)
• Observation: Minimum 4–6 hours after overdose for opioids with half-lives >1 hour; longer for long-acting agents (methadone 24–36 hours); risk of re-sedation as naloxone wears off

Chronic Opioid Use Disorder Management

Medication-Assisted Treatment (MAT) — First-Line

1. 1.Methadone:

• Mechanism: Full μ-opioid agonist; long half-life (24–36 hours) allows once-daily dosing
• Advantages: Highly effective (retention rates >70%); severe withdrawal upon discontinuation promotes compliance; prevents cravings and illicit use
• Dosing: Starting 10–30 mg daily; increase by 5–10 mg every 2–5 days until adequate; typical maintenance 40–100 mg/day (range 20–220 mg/day)
• Administration: Highly regulated in U.S.; requires enrollment in licensed methadone

Life-threatening toxicities

• Respiratory depression: μ receptors on the pre-Bötzinger complex and medullary chemoreceptors blunt the ventilatory response to hypercapnia and hypoxia, producing bradypnea before hypoxemia. This is the mechanism of death in overdose and is potentiated additively by benzodiazepines, alcohol, gabapentinoids, and untreated obstructive sleep apnea — the basis of the FDA boxed warning against routine opioid–benzodiazepine co-prescribing.
• Reversal agent: naloxone, a competitive μ antagonist; titrate to restoration of ventilation, not to full arousal, to avoid precipitated withdrawal. Long-acting agents (methadone, extended-release formulations) outlast naloxone and require prolonged observation or infusion.
• QT prolongation and torsades: methadone blocks the hERG potassium channel; the CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Pain and SAMHSA advise baseline and follow-up ECG monitoring, especially with dose escalation or other QT-prolonging drugs. High-dose loperamide misuse causes the same problem.

Agent-specific hazards

• Meperidine: the metabolite normeperidine accumulates in renal impairment and lowers the seizure threshold; combined with an MAOI it precipitates serotonin syndrome. Listed as potentially inappropriate in older adults by the AGS Beers Criteria.
• Tramadol: serotonin/norepinephrine reuptake inhibition plus a weak μ effect — seizures and serotonin syndrome.
• Codeine: a CYP2D6 prodrug; ultra-rapid metabolizers generate excess morphine, prompting FDA contraindication in children after tonsillectomy/adenoidectomy and in breastfeeding mothers.
• Morphine: active glucuronide metabolites accumulate in renal failure; histamine release causes pruritus, flushing, and hypotension.
• Fentanyl: rapid IV push causes wooden chest truncal rigidity.

• Miosis + bradypnea + depressed consciousness is the classic triad, but the single best next step in a suspected overdose is airway support with bag-valve-mask ventilation and naloxone — never wait for a urine drug screen. Hypoxia severe enough to cause brain injury, or meperidine/tramadol toxicity, can produce normal or dilated pupils; that is the common distractor.
• Standard opiate immunoassays miss fentanyl, methadone, buprenorphine, tramadol, and oxycodone. A negative screen does not exclude synthetic opioid overdose; confirm with LC-MS if the answer hinges on the drug identity.
• Buprenorphine is a partial μ agonist with high receptor affinity: it produces a ceiling on respiratory depression (safety advantage) but will precipitate withdrawal if given to a patient with full agonist still on the receptor. Per ASAM's National Practice Guideline, wait for objective moderate withdrawal (COWS) before induction.
• Naltrexone requires a documented opioid-free interval (roughly a week or more) before initiation, or it precipitates severe withdrawal — the classic vignette trap when the stem offers it for a patient still using.
• In pregnancy, methadone or buprenorphine — not detoxification. ACOG recommends maintenance pharmacotherapy; withdrawal in pregnancy risks relapse and fetal compromise. Neonatal opioid withdrawal syndrome is expected and treatable, not a reason to withhold therapy.
• Adult opioid withdrawal is miserable but not fatal, unlike alcohol or benzodiazepine withdrawal. Adjuncts include the alpha-2 agonists lofexidine or clonidine for autonomic symptoms — they do not treat craving.
• Constipation never tolerizes; every patient started on a scheduled opioid needs a bowel regimen from day one. Docusate alone is inadequate.
• Methadone's exam association is QT prolongation and torsades; its long, variable half-life also means analgesia is short-lived while the drug accumulates, so toxicity classically appears days into titration.